Iberia Pharmaceuticals India Limitedbusiness model
Tap any area to jump to its detail.
Is it a good business, and why? We read the Draft Red Herring Prospectus through the seven domains of John Mullins' framework: the market, the industry, the company's edge and the team behind it. Every rating follows a stated rule, with the evidence shown.
Each domain has its own score; there is no overall score and no buy or sell verdict. Based on the filing dated 17 Sep 2026. This is not investment advice.
Macro-market
Is the overall market big, growing and supported by trends?
Market domain · macro level
The filing states FDI equity inflows in India's manufacturing grew 69% from 2004-14 to 2014-24, with exports expected to reach US$ 1 trillion by 2030.
How it was scored: +10: 4 favourable, 0 neutral and 0 unfavourable among 4 statements and outside facts.
Outside facts: 4 facts found about its market and industry that the filing does not give.
Evidence (0 from the filing, 4 independent)
What credible outside sources say
Found independently, about India
+FDI equity inflows in India's manufacturing sector increased by 69% from Rs. 8,37,191 crore (US$ 97.7 billion) during 2004-14 to Rs. 14,14,742 crore (US$ 165.1 billion) during 2014-24.
“The government reports indicate a 69% increase in FDI equity inflows in the manufacturing sector from Rs. 8,37,191 crore (US$ 97.7 billion) during 2004-14 to Rs. 14,14,742 crore (US$ 165.1 billion) during 2014-24.”
IBEF · Primary source · checked 2026-10-31Found independently, about India
+India has 133 unicorn startups as of October 2026, with eight new entrants in 2026.
“India has 133 unicorn startups as of October 2026, with eight new entrants in 2026, marking a 25% increase over the same period last year.”
IBEF · Primary source · checked 2026-10-31Found independently, about India
+Indian exports are expected to reach US$ 1 trillion by 2030.
“According to Minister of Commerce and Industry, Consumer Affairs, Food and Public Distribution and Textiles Mr. Piyush Goyal, Indian exports are expected to reach US$ 1 trillion by 2030.”
IBEF · Primary source · checked 2026-10-31Found independently, about Healthcare
+Health insurance market share rose to 40.8% from 38.6% in the previous year in FY26.
“Health insurance continued to strengthen its lead within India's non-life insurance sector in FY26, with its market share rising to 40.8% from 38.6% in the previous year.”
IBEF · Primary source · checked 2026-10-31
Micro-market
Is the target customer segment attractive, and does the product beat the alternatives?
Market domain · micro level
The filing states sales grew 11.3% in FY26 and a 2-year CAGR of 18.0% from FY24 to FY26.
How it was scored: +6: 3 favourable, 0 neutral and 0 unfavourable among 3 statements and outside facts; measured figures count double: 1 healthy, 1 to watch, 0 weak.
Outside facts: 3 facts found about its market and industry that the filing does not give.
Worked out from its numbers
- Sales growth
- +11.3%
- Sales CAGR, 2 years
- +18.0%
FY26 on the year before
FY24 to FY26
Evidence (0 from the filing, 3 independent)
What credible outside sources say
Found independently, about Pharmaceuticals
+India hosts over 500 active pharmaceutical ingredient producers, accounting for approximately 8% of the global API market.
“hosts over 500 active pharmaceutical ingredient (API) producers, accounting for approximately 8% of the global API market.”
IBEF · Primary source · checked 2026-10-31Found independently, about Pharmaceuticals
+Indian pharmaceutical companies are projected to achieve a revenue growth of 9-11% in FY25.
“Indian pharmaceutical companies are projected to achieve a revenue growth of 9-11% in FY25.”
IBEF · Primary source · checked 2026-10-31Found independently, about Pharmaceuticals
+In Q1 2025, the Pharma & Healthcare Sector saw 71 deals worth Rs. 22,279 crore (US$ 2.6 Billion).
“In Q1 2025, the Pharma & Healthcare Sector saw 71 deals worth Rs. 22,279 crore (US$ 2.6 Billion).”
IBEF · Primary source · checked 2026-10-31
Industry
Is the industry structurally attractive: suppliers, buyers, rivals, new entrants and substitutes?
Industry domain · macro level
+10: 3 favourable, 0 neutral and 0 unfavourable among 3 statements and outside facts.
How it was scored: +10: 3 favourable, 0 neutral and 0 unfavourable among 3 statements and outside facts.
Outside facts: 3 facts found about its market and industry that the filing does not give.
Compared with: the listed companies in its industry group. Classified as Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals, 197 listed companies. The model's own pick of industry group agrees.
Worked out from its numbers
- Listed companies in its industry group
- 197
- Operating margin across the industry group
- 14.3% middle
Pharmaceuticals & Biotechnology
5.8% to 21.2% for the middle half of 179 companies
Evidence (0 from the filing, 3 independent)
What credible outside sources say
Found independently, about Pharmaceuticals & Biotechnology
+In 2025, the BioIndustrial segment was valued at US$ 90.20 billion, making it the largest segment of India's BioEconomy.
“In 2025, BioIndustrial emerged as the largest segment of India's BioEconomy, valued at US$ 90.20 billion, followed by BioPharma at US$ 64.50 billion.”
IBEF · Primary source · checked 2026-10-31Found independently, about Pharmaceuticals & Biotechnology
+India hosts over 500 active pharmaceutical ingredient producers, accounting for approximately 8% of the global API market.
“hosts over 500 active pharmaceutical ingredient (API) producers, accounting for approximately 8% of the global API market.”
IBEF · Primary source · checked 2026-10-31Found independently, about Pharmaceuticals & Biotechnology
+India's biotechnology market size was approximately US$ 37.09 billion in 2025.
“India's biotechnology market size was valued at approximately US$ 37.09 billion in 2025”
IBEF · Primary source · checked 2026-10-31
Competitive advantage
Can the company keep an edge, and does the business model make economic sense?
Industry domain · micro level
The filing states IBERIA PHARMACEUTICALS INDIA LIMITED reported an operating margin of 17.6% in FY26, which is 17.6% against listed peers.
How it was scored: +10: measured figures count double: 5 healthy, 0 to watch, 0 weak.
Compared with: the listed companies in its industry group. Classified as Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals, 197 listed companies. The model's own pick of industry group agrees.
Worked out from its numbers
- Operating margin
- 17.6%
- Net profit margin
- 11.5%
- Return on equity
- 21.6%
- Debt to equity
- 0.37x
- Cash conversion
- 99% of profit
- Operating margin against listed peers
- 17.6%
- Net profit margin against listed peers
- 11.5%
- Debt to equity against listed peers
- 0.37x
- Cash conversion against listed peers
- 0.99x
FY26; -7.8 points on the year before
FY26
FY26
FY26
operating cash flow ₹11.0 Cr against net profit ₹11.1 Cr, FY26
69 of 175 against its sub-industry; their middle value is 13.8%
58 of 159 against its sub-industry; their middle value is 6.9%
121 of 173 against its sub-industry; their middle value is 0.17x
61 of 129 against its sub-industry; their middle value is 0.90x
Team: aspirations
What do the promoters want from this IPO: to sell down or to grow the company?
Team domain
+10: measured figures count double: 1 healthy, 0 to watch, 0 weak.
How it was scored: +10: measured figures count double: 1 healthy, 0 to watch, 0 weak.
Worked out from its numbers
- Promoter holding before the IPO
- 96.4%
- Proceeds used to repay debt
- 13%
₹51.8 Cr of ₹94.8 Cr for growth (capex, acquisitions, technology, marketing)
Team: execution
Can the team deliver what the industry demands?
Team domain
The filing and the sources we checked say too little about this to judge it.
How it was scored: No fact was found for this domain.
Team: connections
Does the team have the ties across the value chain: customers, suppliers, partners?
Team domain
The filing and the sources we checked say too little about this to judge it.
How it was scored: No fact was found for this domain.
How to read this
What the ratings mean, where the evidence comes from, and what this page is not.
Three kinds of evidence, always labelled
What the company says comes from its own offer document, with the page it came from. It is a claim, not a finding. Worked out from its numbers is arithmetic on the filing's own financial statements and issue terms. Independent sources are outside publications we trust, with the name, tier and date.
How a rating is set
- Every piece of evidence points one way: favourable (+1), neutral (0) or unfavourable (-1). The score is the average of those, times ten, so it runs from -10 to +10.
- It is an average, not a total: twelve favourable facts score the same as four. Only their balance counts.
- Figures worked out from the filing's numbers count double: healthy is +1, to watch is -0.5, weak is -1. A figure and its peer comparison count once.
- The company's own statements and the outside facts about its market and industry are each read by the model, which only says which way a sentence points; every sentence stays visible.
- “Not enough evidence” appears only when nothing at all was found for the domain.
Which outside sources count
Facts about a company's market and industry come from a fixed list: regulators and exchanges (SEBI, NSE, BSE, MCA, RBI), government and industry bodies, credit-rating agencies, and established business press. Blogs, forums, social media and Wikipedia are excluded. Each is kept with the exact sentence it rests on. We do not check what the offer document itself says against the web: that is SEBI's job.
About the framework
The seven domains come from John Mullins' The New Business Road Test, written for new ventures. We adapt each domain to what an IPO document can show. The author has not reviewed or endorsed this analysis. Read it with the filing, not instead of it.